Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that women with polycystic ovary syndrome phenotypes A and B had the highest prevalence of metabolic syndrome, and that the visceral adiposity index may help predict metabolic risk.

This study found no significant differences in metabolic characteristics between different phenotypes of PCOS or between women with PCOS and healthy controls among reproductive-aged Iranian women.

This review explores the relationship between androgenetic alopecia and metabolic syndrome, suggesting an association that supports considering cardiovascular risk assessments in patients with this type of hair loss.

This review discusses emerging concepts in PCOS from the AEPCOS 2010 meeting and reports no clinical findings; it suggests that the transition of care in congenital adrenal hyperplasia could inform PCOS adolescent care.

This meta-analysis confirmed associations between some androgenic and metabolic parameters in women with PCOS, suggesting that these measurements might help predict metabolic risk in this population.

This study found that metabolic syndrome or related metabolic issues are common among the family members of women with polycystic ovary syndrome.

This article reviews the challenges in treating PCOS, noting the potential benefits of insulin sensitizers on ovulatory function and pregnancy outcomes, and calls for more long-term studies on metabolic interventions.

This study found that both metformin and rosiglitazone improved ovulation and insulin sensitivity in women with PCOS, with rosiglitazone showing a more pronounced increase in adiponectin levels.

The researchers reported that among Mediterranean Sicilian women with PCOS, Phenotype B exhibited the most severe metabolic abnormalities, notably obesity and altered glucose metabolism, whereas Phenotype D showed no such issues.

In this study of women with PCOS, hirsutism strongly correlated with metabolic abnormalities, while acne and androgenic alopecia were not clear markers of biochemical hyperandrogenemia or metabolic dysfunction.

This study concluded that the best approach for detecting Androsta-1,4,6-triene-3,17-dione administration in horses is monitoring the metabolites M1b or M4 in urine, detectable up to 77 hours post-administration.

This study found that older women with polycystic ovarian syndrome are more likely to experience metabolic syndrome and have different metabolic and reproductive profiles than younger women.

This study found that older age and obesity are predictors of metabolic syndrome and insulin resistance syndrome among infertile Vietnamese women with PCOS.

This study highlights that lower testosterone in men and higher testosterone in women are linked to increased risks of metabolic syndrome and type 2 diabetes, with associated skin diseases indicating potential cardiovascular complications.

This study found that increasing the follicle number criteria for diagnosing PCOS to 25 per ovary excluded some women who continue to show evidence of metabolic risk.

This study found that irregular menstrual cycles in Brazilian adolescents were significantly associated with a higher occurrence of metabolic syndrome and polycystic ovary syndrome indicators.

This study reports that in women with non-tumor hyperandrogenism, a decrease in serum testosterone from insulin-sensitizing therapy like metformin may indicate a low likelihood of having an androgen-secreting tumor.

Obese Hispanic women with PCOS are at higher risk for metabolic problems than non-Hispanic white women.

This review found that chromium supplementation has limited effects on weight reduction, glucose control, lipid profile, and hormonal balance in women with PCOS, highlighting the need for further research.

This study found that L-cystine, D-pantothenat, and miliacin can enhance the metabolic capacity and proliferation of human keratinocytes, with a combination of these additives potentially providing synergistic benefits in growth media.

In this study, long-term normalization of testosterone levels in postmenopausal women with hyperandrogenism did not improve body mass index, glucose, or lipid metabolism.

This study found that normal ALT levels in women of reproductive age are linked with metabolic and androgenic abnormalities, suggesting ALT could be used beyond liver disease diagnoses.

This study found that a combination of cyproterone acetate and ethinyl estradiol over one year did not affect glucose tolerance but increased total cholesterol, HDL cholesterol, and triglycerides in patients with moderate hyperandrogenism.

In this study, researchers found that overweight and obese women with polycystic ovary syndrome showed adverse changes in glucose metabolism over time, highlighting the importance of early intervention to prevent cardiometabolic diseases.

This study found that relatives of women with symptoms of oligo-amenorrhoea and hirsutism experienced higher rates of hirsutism, menstrual disorders, infertility, childlessness, diabetes, and hypertension compared to relatives of symptomless women.

This report describes the first known case of diffuse idiopathic skeletal hyperostosis in a woman under 40, associated with both metabolic syndrome and polycystic ovarian syndrome.

This article reviews the problem of acne and hirsutism in women, highlighting the effectiveness of combined oral contraceptives containing drospirenone and levomefolate calcium in managing these conditions and polycystic ovary syndrome, but no new clinical results are reported.

This study found that women with polycystic ovary syndrome in the Black Sea Region had higher levels of androgens, obesity, and insulin resistance, increasing their risk of metabolic syndrome compared to healthy women.

This review highlights that effective management of PCOS-related dermatological issues, such as hirsutism and acne, requires a multidisciplinary approach involving hormonal therapies, metabolic interventions, and lifestyle changes.

This study observed that women with PCOS exhibited higher levels of triglycerides, fasting insulin, HOMA-IR, total testosterone, DHEAS, and LH/FSH ratio, and lower HDL cholesterol compared to healthy controls, with these markers varying across different PCOS phenotypes.